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Abstract
Background: It is critically important to conduct research on stigmatized conditions, to include marginalized
groups that experience stigma, and to develop interventions to reduce stigma. However, such research is ethically
challenging. Though superficial reference is frequently made to these widely acknowledged challenges, few
publications have focused on ethical issues in research on stigmatized groups or conditions. In fact, a brief literature
review found only two such publications.
Main text: At a recent Science of Stigma Reduction workshop comprising 60 stigma researchers from the USA and
low and middle-income countries, the need for more robust and critical discussion of the ethics of the research
was highlighted. In this paper we describe, illustrate through cases, and critically examine key ethical challenges
that are more likely to arise because a research study focuses on health-related stigma or involves stigmatized
groups or conditions. We examine the ethics of this research from two perspectives. First, through the lens of
overprotection, where we discuss how the perception of stigma can impede ethical research, disrespect research
participants, and narrow the research questions. Second, through the lens of research risks, where we consider how
research with stigmatized populations can unintentionally result in harms. Research-related harms to participants
include potential breaches of confidentiality and the exacerbation of stigma. Potential harms also extend to third
parties, including families and populations who may be affected by the dissemination of research results.
Conclusions: Research with stigmatized populations and on stigmatized conditions should not be impeded by
unnecessary or inappropriate protective measures. Nevertheless, it may entail different and greater risks than other
health research. Investigators and research ethics committees must be particularly attentive to these risks and how
to manage them.
Keywords: Stigma, Ethics, Global health, Research ethics, Vulnerability, De-normalization, Research risks,
Confidentiality, Privacy
Background
Stigma is common globally for multiple and diverse
reasons. Patients may be stigmatized because they have
diseases, such as HIV/AIDS, leprosy, lung cancer, epilepsy,
or schizophrenia, or for characteristics or behaviors that
are regarded as undesirable or “socially deviant”, e.g.
because they smoke, inject drugs, are obese, are sexually
or gender non-conforming, or drink alcohol during
pregnancy. The nature of stigma varies, but stigma and its
effects are found everywhere.
It is critically important to conduct research on stigma-
tized conditions, to include marginalized groups that ex-
perience stigma, and to develop interventions to reduce
stigma. However, such research is operationally and ethic-
ally challenging. As we illustrate in this paper, individuals
who experience stigma may be hard to recruit, partici-
pants may be at higher risk of certain harms, and the re-
sults of research could lead to further marginalization or
other negative effects on at-risk communities.
In this paper, we describe, illustrate through cases, and
critically examine key ethical challenges that are more
likely to arise because a research study focuses on
health-related stigma or involves stigmatized groups or
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conditions. Our goals are threefold: (1) to help re-
searchers, research ethics committees (RECs), and other
stakeholders to appreciate the range of ethical challenges
that research with stigmatized groups or on stigmatized
conditions presents; (2) to make recommendations re-
garding those challenges, where that is possible given
existing resources; and (3) to identify areas where the
challenges merit further work.
We approach this topic with an understanding that
there are commonalities across populations, conditions,
and types of research. The stigma that makes research
with HIV-positive adolescents ethically challenging, for
example, has some features in common with the stigma
that poses difficulties for responsible research on the
genetic inheritance of schizophrenia. We hope lessons
learned in one area, suitably adjusted in the light of con-
textual differences, can help researchers facing similar
challenges in another.
In this paper, stigma is understood as a socially con-
structed phenomenon that occurs when members of a
group experience status loss or discrimination on the
basis of some shared characteristic that is deemed un-
desirable by a dominant group [1]. Its effects can occur
through attitudes and beliefs internalized by stigmatized
individuals (self-stigma), through overt discrimination by
others (experienced or enacted stigma), and through the
fear of such discrimination (felt stigma). This broad def-
inition is intended to be maximally inclusive of situa-
tions in which researchers encounter the challenges we
discuss.
In June 2017, the Fogarty International Center of the
National Institutes of Health hosted a three-day work-
shop on ‘The Science of Stigma Reduction: New Direc-
tions for Research to Improve Health’. Workshop
attendees included approximately 60 researchers from
the USA and low and middle-income countries whose
work addresses stigma related to different disease areas
and populations. During one session of the workshop,
participants discussed the ethical challenges they faced
when conducting research with stigmatized groups or on
stigmatized conditions. Multiple participants noted a
lack of guidance specific to these challenges.
We conducted a literature review using two electronic
database sources, Google Scholar and PubMed. We
searched for all papers, in English, containing the terms
“stigma” and “ethics” anywhere in the article. We manu-
ally reviewed the titles and abstracts of the resulting publi-
cations to determine their relevance to health-related
stigma and to research ethics.
Most of the ethics literature relating to stigma focuses
on public health interventions, such as anti-tobacco or
obesity campaigns. We identified only two papers that
focused on the ethics of research on stigma or involving
stigmatized groups [2, 3]. Researchers and research
ethicists are clearly cognizant of ethical challenges aris-
ing from stigma research, because it is mentioned in
multiple places in prominent guidance documents [4, 5].
However, the issue is typically diluted or subsumed
under broader categories. For example, many popula-
tions at risk for stigma are considered to be ‘vulnerable’,
but this label is also applied to populations that are not
stigmatized, such as children. At other times, stigma is
raised in the context of a specific disease or type of re-
search (e.g. HIV/AIDS or genetic research), where valu-
able insights into how to conduct research ethically have
been developed, but the siloed nature of research means
that these insights are not always communicated to re-
searchers working in other topic areas for which stigma
is an issue.
The discussion at the workshop, subsequent follow-up
with participants, and the literature review, highlighted
multiple ethical issues. From these, we identified a sub-
set that appear more likely to arise because a research
study focuses on health-related stigma or involves stig-
matized groups or conditions. For each, we selected a
case study – one that had either been contributed by a
workshop participant or described in the literature –
that illustrates the ethical issue, and applied ethical prin-
ciples – as articulated elsewhere in research ethics – to
analyze it.
Ethical challenges in stigma research
Overprotection
Because they are often severe and hard to treat or pre-
vent, there is frequently a particular need to conduct re-
search into stigmatized conditions. Likewise, people who
experience stigma are typically marginalized and in
greater need of assistance than those with a socially ac-
cepted status. More research is also needed into inter-
ventions to reduce stigmatization itself, given its
negative effects on health and wellbeing. Despite the
need, substantial barriers impede this research.
One key barrier is the link between stigma and per-
ceived vulnerability. In research ethics, ‘vulnerability’ has
traditionally been used to label populations that are
thought to be at greater risk of harm or some other wrong
[6], including children, people in subordinate positions or
who are poor, ethnic and racial minorities, and the men-
tally ill [7]. Protections for vulnerable populations are
sometimes enshrined in laws; even outside of regulatory
restrictions, funders and RECs are often reluctant to allow
research with populations regarded as vulnerable. This
traditional conceptualization of vulnerability may lead to
two forms of overprotection: overprotection through ex-
clusion from research, and through providing inappropri-
ate protections in research. The first two cases illustrate
these problems. The third case illustrates a different form
of overprotection, which arises because of the
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presumption that stigma is invariably harmful and coun-
terproductive. This last case raises the question of whether
there are contexts in which health researchers should in-
vestigate beneficial effects of de-normalizing certain
behaviors.
Case 1. Adolescents excluded from PrEP studies
People infected with HIV, children living with family mem-
bers with HIV, and children who are orphaned because of
HIV are frequently stigmatized [8]. This stigma reduces
health-seeking behaviors and is a major obstacle to treat-
ment and prevention efforts. Adolescents represent a large
proportion of people living with HIV globally: one-third of
all new HIV infections in 2016 occurred in adolescents
aged 15–19 years [9]. In sub-Saharan Africa, gendered
power disparities, gender-based violence, and the conse-
quent inability to negotiate safer sex practices, exacerbate
the vulnerability of adolescent girls to HIV. Adolescent sex-
ual activity is also frequently stigmatized. While antiretro-
viral PrEP offers a female-centered approach, with
demonstrated prevention potential in adherent women
aged 18 or over, adolescents below 18 are inadequately rep-
resented in PrEP trials [10]. Stringent ethical–legal guide-
lines and RECs in South Africa require parent/guardian
consent to participate in clinical trials for everyone under
the age of 18 because they are considered to be vulnerable.
Moreover, in the worst hit provinces, one-fifth of children
in many communities have lost parents (often to AIDS),
and one-third do not live with either biological parent [11].
There is often no formally assigned guardianship, especially
in rural communities. The adolescent girls who are most at
risk are those most affected by the negative effects of sec-
ondary HIV stigma (that is, stigma attached to those who
are associated with individuals stigmatized because of their
HIV status). Yet, tragically, these are the same girls whom it
is most difficult to enroll into studies into ways to prevent
HIV. The cause of their stigmatization – coming from
HIV-affected families – not only deters them from engaging
with HIV researchers and clinicians, but also makes it par-
ticularly hard to get consent from a parent to enroll them
into clinical trials.
Case 2. Schizophrenia patients and consent capacity
The Genomics of Schizophrenia in South African Xhosa
People study was a psychiatric genomics study that exam-
ined gene mutations in Xhosa people with schizophrenia
and unaffected controls [12]. As in many other countries,
schizophrenia is heavily stigmatized in South Africa. The
REC that approved the study required screening for deci-
sional capacity for participants with schizophrenia. The
underlying assumption was that schizophrenia was liable to
impede the capability to make informed decisions, and
schizophrenia patients needed particular protection against
inappropriate enrollment. Interestingly, use of an informed
consent screening tool to evaluate the quality of under-
standing of the research study demonstrated that, while
many individuals with schizophrenia struggled to under-
stand certain elements of the study during recruitment, so
did some of the unaffected controls [13]. Rather than sim-
ply excluding people with schizophrenia who did not ex-
hibit sufficient understanding, the researchers developed an
iterative learning process to use with all potential partici-
pants. Using a brief screening tool, they assessed under-
standing of different research study elements, such as the
study’s aim, risks, and benefits. This allowed them to revisit
and better explain elements that were hard to grasp, im-
proving participant understanding. The iterative process,
while more time consuming, demonstrated large improve-
ments in understanding in both study groups [13].
Case 3. Public health interventions to prevent fetal alcohol
syndrome
Alcohol consumption during pregnancy is associated with
fetal alcohol spectrum disorders (FASD), which encompass a
range of mental, physical and neurodevelopmental deficits in
infants, including fetal alcohol syndrome (FAS) [14]. Global
prevalence of alcohol consumption during pregnancy is esti-
mated at 9.8%, and an estimated 119,000 babies are born
with FAS each year [15]. New behavioral interventions to re-
duce alcohol consumption before and during pregnancy are
urgently needed, including in countries where contact with a
clinician before or early in pregnancy is not routine for many
women. One plausible basis for public health interventions is
to attempt to de-normalize drinking during pregnancy
through, for example, targeted warning labels on alcoholic
drinks or advertising campaigns. The de-normalization of
smoking is widely thought to have contributed to dramatic
declines in tobacco use in many high-income countries.
However, there are concerns that public health campaigns
that encourage people to regard drinking during pregnancy
as socially unacceptable would also exacerbate the
stigmatization of people with FASD and their parents.
Should researchers develop and study such de-normalizing
interventions?
Critical discussion
Overprotection, even if well-intentioned, can have nega-
tive consequences. In Case 1, adolescents are prevented
from participating in research that would address their ur-
gent need for safer, more effective HIV prevention. A
population in great need of an effective intervention may
therefore be substantially delayed in receiving it. In Case
2, people who might make a meaningful contribution to
psychiatric genomics research could have been excluded,
and unaffected controls could have been recruited without
proper understanding of the study. RECs typically voice
concern about the capacity of people with severe mental
illness to give informed consent. It then becomes the
Millum et al. BMC Medicine           (2019) 17:84 Page 3 of 9
responsibility of the research team to demonstrate ad-
equate consent. However, in being overly cautious of pro-
tecting against the exploitation of a stigmatized group,
researchers may not pay sufficient attention to the par-
ticular needs of that group to promote their inclusion, or
recognize the complexities of the research study elements
that may impact on understanding for everyone.
Vulnerability
Overprotection is closely related to labeling a population
as ‘vulnerable’. Once a stigmatized population is classi-
fied as vulnerable, protection is required, the default of
which is frequently exclusion from research. The trad-
itional or subpopulation approach to vulnerability, ac-
cording to which entire populations are classified as
vulnerable, also has a stereotyping effect because the
label ‘vulnerable’ cannot be easily removed and can
thereby exacerbate stigmatization [16]. RECs tend to use
the concept of vulnerability in this traditional way.
An alternative view of vulnerability may help re-
searchers working with stigmatized groups to address
this problem. Instead of the subpopulation approach, we
can consider vulnerability in a layered way [17]. This
concept of vulnerability is relational: if the context
changes, the person may no longer be vulnerable in that
way [4]. Some layers may be related to problems with in-
formed consent, others to violations of human rights or
social circumstances, and they may overlap or com-
pound. In this way, the layered view of vulnerability
shares features with the concept of intersectionality.
Intersectionality refers to the way that an individual may
belong to multiple groups, each of which faces discrim-
ination, and the forms of discrimination experienced by
someone with this overlapping membership may not be
reducible to the discrimination experienced by individ-
uals who belong to just one of the groups [18].
For example, a woman, in herself, is not vulnerable,
but a woman living in a country that is intolerant of re-
productive rights acquires a layer of vulnerability. In
turn, an educated and well-off woman in that same
country might overcome some of the consequences of
such intolerance, while a poor woman acquires another
layer of vulnerability. Moreover, an illiterate, poor
woman acquires still another layer. On this view, vulner-
ability is not a binary category: the metaphor of layers
gives flexibility to the concept.
The layered view of vulnerability can help to evaluate
proposed research projects involving stigmatized groups.
First, researchers should identify potential layers of vul-
nerability. Second, they should consider strategies for
managing each layer in ways that seek to safely include
– as oppose to exclude – potential participants [19].
RECs and researchers should design tools to empower
research participants – helping them to make their own
choices and pursue their own goals – as well as provid-
ing adequate safeguards and protections. As DuBois et
al. recommend, “Offer as many protections as necessary
and as few as possible [20].”
For example, in Case 1, age of consent can be considered
as a layer of vulnerability. In this case, the researchers seek-
ing to include adolescent girls sought to manage the vulner-
ability by using community engagement mechanisms to
promote appropriate consent and protection. Members of
the local community, including adolescent girls, were asked
to advise on how to involve this group in research in ways
that retained trust in the research enterprise, encouraged
them to seek care, and reduced the risks of exacerbating
HIV-related stigma. The solution proposed and presented
to the REC involved having a community adult proxy to
serve as guardian for adolescent participants who lacked a
formal guardian, as well as comprehension tests for the par-
ticipants themselves. The approach of engaging the com-
munity also drew attention to the existence of child-headed
households and catalyzed community support for them.
For Case 2, if we consider decisional capacity as a layer of
vulnerability that affects participants to varying degrees, the
focus during recruitment becomes more about how to as-
sist understanding of the research study than about who to
exclude. In this way, we guard against overcautious exclu-
sion and perpetuating negative stereotypes and stigma.
De-normalization
A final issue relating to overprotection concerns the re-
search questions that are asked about stigma, as Case 3
illustrates. Stigma and stigmatization have been the tar-
get of sharp critiques from public health advocates and
social scientists for decades. Stigmatization, it is argued,
threatens populations by driving its targets to the mar-
gins of society and reinforcing negative stereotypes.
Stigmatization has therefore been denounced as morally
repugnant, as unjust, and as a violation of human rights
[21]. In the context of FASD, multiple commentators
have raised concerns that behavioral interventions to re-
duce alcohol consumption during pregnancy might in-
crease the felt or enacted stigma of people with FASD
and their parents [22]. Moreover, they claim, stigmatiz-
ing alcohol use in pregnancy might be counterproduct-
ive by discouraging women from admitting alcohol use
or seeking prenatal care [23, 24].
Evidence suggests that alcohol warning labels increase
awareness [25], and graphic warning labels with pictures
are effective in reducing tobacco use [26]. However,
there is a paucity of data regarding the net benefits or
harms of interventions that might reduce drinking dur-
ing pregnancy through such public health campaigns.
Public health campaigns that aimed to de-normalize cer-
tain forms of previously socially acceptable behavior,
such as smoking, have had some success in reducing the
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harmful behaviors they target [27, 28]. They may also
have indirect negative consequences, such as when lung
cancer patients are stigmatized because they are seen as
responsible for their disease [29]. The line between
de-normalization that leads individuals engaging in un-
healthy behaviors to regard those behaviors as no longer
socially acceptable, and the status loss and discrimin-
ation associated with stigma, is difficult to draw.
In summary, FASD is a huge health problem, we lack
proven effective interventions, and there are several poten-
tial de-normalizing interventions that might have beneficial
and potentially negative effects. In such circumstances, it
seems prudent to conduct research to find out what the ac-
tual effects would be. We see this as a challenge to both
critics and proponents of public health campaigns that
could create or exacerbate stigma. Those who think we
should not even consider research to test de-normalizing
interventions need to provide good reasons for their case;
for example, high-quality evidence that the strategy would
be ineffective or harmful on balance. Speculative claims
about harm are insufficient. On the other hand, those who
think we should consider interventions that risk stigmatiz-
ing pregnant drinkers should develop de-normalization in-
terventions intended to minimize harms and maximize
benefits. Such interventions need rigorous study so that
they will be adopted (or not) on the basis of data regarding
their effects.
Research risks
Stigma poses additional risks to research participants. Fear
of stigmatization and discrimination affects individuals’
willingness to leave their homes, engage publicly, and ob-
tain healthcare services. As a result, some stigmatized
groups are difficult to access for healthcare and research.
One key challenge, then, is how researchers should inter-
act with the most severely stigmatized populations, when
the stigma is itself a powerful barrier, and association with
the research may lead to substantial harms. Patients with
stigmatized conditions may also be at greater risk of
harms from the research procedures themselves, where
they risk perpetuating stigma or re-traumatizing partici-
pants. Finally, research risks are not limited to research
participants, but can also affect their families and commu-
nities. The following cases illustrate these points.
Case 4. African immigrants living with HIV (unpublished
observations, Deepa Rao)
African immigrant communities in the Seattle area tend
to be small and tightknit, with little anonymity. Conse-
quently, many community members living with HIV fear
inadvertent disclosure of their HIV status. They are reluc-
tant to be seen in HIV care-related settings, especially by
other community members. They avoid tangible associ-
ation with the disease, including participation in
HIV-related research, and appear to be unfamiliar with
clinical research in general. They have significant concerns
about having their data collected and personal information
recorded, especially related to HIV. A related fear is that
disclosure of their HIV status may jeopardize their immi-
gration status. Many African immigrants also struggle
with language and literacy barriers, making the conveying
of sensitive information and reassurances challenging.
Case 5. Women with epilepsy (unpublished observations,
Gretchen Birbeck)
Women with epilepsy are stigmatized in many settings.
Focus group discussions with women with epilepsy in
communities in Zambia revealed traumatic stories of
spousal abandonment in the days, months, and some-
times years after their condition developed or became
public knowledge. Hearing about this was frightening for
other women in the focus groups who had not (yet?)
been abandoned by their spouses. In the same study,
based on requests from local support groups, hats and
t-shirts making reference to bringing epilepsy “out of the
shadows” were distributed to those living with the condi-
tion. On bringing these items home, some women were
physically and verbally abused by their family members
who feared that their condition would result in the
whole family being stigmatized.
Case 6. The Maori and a “gene for” aggression
Monoamine oxidases (MAOs) are a family of enzymes
that break down neurotransmitters. In the early 2000s,
studies identified a correlation between an MAO-A gene
variant and anti-social behavior in Caucasian men who
were abused or neglected in childhood [30]. It was de-
scribed in a 2004 Science report as a “warrior” gene [31].
In 2006, researchers from New Zealand’s Institute for En-
vironmental Science and Research presented the results of
their research on the MAO-A gene variant in a Maori (in-
digenous New Zealand) population under the title, ‘Track-
ing the evolutionary history of the warrior gene in the
South Pacific.’ One of the researchers involved commen-
ted: “Obviously, this means they are going to be more ag-
gressive and violent, and more likely to get involved in
risk-taking behavior like gambling… It is controversial be-
cause it has implications suggesting links with criminality
among Maori people [32].” Headlines around the world
quickly reflected this claim, which played into existing ste-
reotypes about the Maori, despite the scientific basis for
the behavioral claims being debunked [30].
Critical discussion
As these cases illustrate, research with stigmatized
groups or on stigmatized conditions may pose additional
risks that would not typically arise in research on popu-
lations who were not stigmatized. Two types of risk
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warrant particular attention: risks related to privacy and
confidentiality, and risks to non-research participants.
Privacy & confidentiality
Researchers have a duty to preserve the privacy and confi-
dentiality of all participants. This duty is frequently more
weighty and broader in scope for research with stigmatized
groups or on stigmatized conditions [33]. It is weightier be-
cause the negative consequences of breaches are often
higher; for example, knowledge, or even suspicion of a diag-
nosis of leprosy might lead to someone being socially ostra-
cized. There may even be legal consequences; for example,
people who inject drugs face stigma, but are also likely to
be breaking the law. It is broader insofar as the scope of the
information that needs to be kept private to protect partici-
pants may be greater than in other research contexts. For
example, simply being seen visiting a clinic that is known to
conduct HIV-related research may imply to others that a
participant has HIV.
Where the risk to participants of being identified from
research data is high, full anonymization should be con-
sidered and implemented as soon as the scientific goals
of the research allow. Whether such anonymization is
possible or desirable will depend on the nature of the re-
search. For example, biobanks may de-identify speci-
mens, but modern genetics techniques mean that it is
no longer possible to guarantee against re-identification
[34]. Some funding organizations and journals require
researchers to make their data publicly available. Cau-
tion should be exercised in how this is done for research
where re-identification of participants would put them
at considerable risk [4]. For research participants who
engage in illegal activities, additional protections are
sometimes available. For example, in the USA, the Na-
tional Institutes of Health issues Certificates of Confi-
dentiality that protect researchers from being compelled
to release identifying information about participants dur-
ing legal proceedings [35].
In many cases, the risk of breach of confidentiality does
not come from the data that has been collected, but from
the interaction of participants with researchers, such as
when the researchers are known to be studying a stigma-
tized condition or population. Depending on the popula-
tion or site, this risk can sometimes be mitigated. For
example, Sugarman et al. describe a process for develop-
ing site-specific participant safety plans, which they used
in a multinational HIV prevention study with people who
inject drugs [36]. The plans were based on local legal and
policy assessments, and semi-structured interviews with
key stakeholders (such as people who inject drugs, clini-
cians who treat drug use or HIV, law enforcement officials,
and policy experts). Distinctive features of the plans in-
cluded describing the study as being about HIV preven-
tion rather than about drug users or people with HIV/
AIDS, conducting the study at sites where several medical
services were provided, and training staff on confidential-
ity and stigma reduction. In another HIV study, this time
of group cognitive-behavioral therapy to reduce alcohol
use among HIV-infected outpatients in Western Kenya,
the investigators describe several changes to their prac-
tices to protect participants from breaches of confidential-
ity. These included disregarding the cultural expectation
that consent from women would be obtained only after
permission was granted by the male head of household,
and ceasing to offer free taxis to the study site once it was
noted that this called attention to participants [37].
Risks to third parties
The core value of research cannot be realized unless its re-
sults are publicized. However, as Case 6 shows, it matters
which results are disseminated and how. There, the fram-
ing of the results encouraged a simplistic understanding
of the underlying science that played into existing negative
stereotypes, and was, predictably, picked up by the media.
Achkar and Macklin, who describe the pros and cons of
reporting findings from research on undocumented immi-
grants in the USA, raised parallel concerns about possible
uptake [2]. The results seemed to imply that undocu-
mented immigrants were more likely to transmit tubercu-
losis than documented immigrants or US-born persons.
Would publishing these findings exacerbate the
stigmatization of undocumented immigrants?
How the results of research will be disseminated, and
how they might be used or misused, should be considered
in the planning stage of a research study. Researchers
should plan, for example, how to convey their results to
policy-makers, and how to minimize the risks of misinter-
pretation. When planning to study a population at risk for
stigma, researchers should ask themselves: is this research
project likely to lead to knowledge that benefits this popu-
lation? If not, then they probably should not be asking
those research questions, or should redesign the study. In
their discussion of the study of immigrants and tubercu-
losis, Achkar and Macklin are careful to emphasize that
publishing the data relating to undocumented immigrants
had a plausible connection to public health interventions
likely to benefit those immigrants.
Some potential ‘group harms’ [38] from stigma research
could be addressed through appropriate community en-
gagement. Community engagement provides an oppor-
tunity to inform community members about the research,
and to get permission for the research from community
representatives (over and above the consent of individual
research participants). Engaging with communities is not
just about getting permission; it is about understanding
the perspectives of people who may be affected, the risks
they perceive, and how health-related stigma is perpetu-
ated in that specific context. This is critical when outside
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researchers attempt to work with stigmatized populations;
for example, high-income country researchers working on
stigma in low or middle-income countries. At its best,
community engagement means involving stigmatized
groups in the research process, and empowering them
through ownership of the research [39].
There is extensive literature on how to involve communi-
ties in planning and conducting research, including
non-traditional communities, such as patient groups [40, 41].
Researchers might draw on the existing work regarding com-
munity engagement and community advisory boards [42].
Best practices for research with indigenous peoples may also
provide helpful lessons for other research with marginalized
populations, including those who experience stigma [5, 43].
It is worth noting, however, that this is another area in which
the distinctive nature of stigma sometimes supports a
different approach. For example, for research on a
non-stigmatized condition, the goals of community engage-
ment might be best realized by involving community mem-
bers in data collection. By contrast, research with HIV and
tuberculosis patients suggests that these patients may prefer
to interact with non-community members to reduce the
risks of a breach of confidentiality [44]. Again, careful en-
gagement with community members, especially those drawn
from affected populations, can help to identify such risks.
Another third party that can be affected by research with-
out being enrolled is the participant’s family. In Tekola et al.’s
discussion of informed consent for genetic research on podo-
coniosis in southern Ethiopia, they note: “Patients were con-
cerned that the research might publicize podoconiosis as a
familial condition and would aggravate the stigma by label-
ling children of affected families as ‘at-risk’” [3].
Again, to grasp the potential risks, researchers need to
learn about the local social and cultural context, and how
affected individuals perceive potential risks. In this case,
engagement with community members helped to identify
a potential problem with secondary stigma. Consequently,
researchers may need to protect family members by avoid-
ing the identification of households whose members are
research participants. As Case 5 illustrates, researchers
may also need to consider how to protect participants
from family members who might react poorly to research
participation or publicizing a diagnosis. Finally, there is a
question of whether other parties should be asked for con-
sent, in addition to the participants themselves. Tekola et
al. write: “Most participants said that patients are usually
free to make their own decisions about participation in re-
search. However, in relation to genetic research on podo-
coniosis, most participants suggested involving the head
of the family, or the family as a whole in the consent
process. Because of the prevailing stigma attached to a
podoconiosis-affected family, they (by implication) pre-
ferred that the ownership of every sample for genetic
study should belong to the whole family [3].”
Whether and how family members, or other third parties
who might be affected by research, should be involved in de-
cisions about research participation remains under-explored
in research ethics.
Conclusions
Research with stigmatized groups or on stigmatized con-
ditions can pose substantial ethical challenges. That is a
reason to conduct the research thoughtfully; it is not a
reason against conducting the research at all. In thinking
about research with stigmatized populations, re-
searchers, funders, and RECs should avoid overprotect-
ing these populations, whether by excluding them
altogether, by instituting excessive protections, or by
refusing to engage with controversial questions.
That said, research with stigmatized groups or on stig-
matized conditions can entail different and greater risks
than other areas of health research. Investigators and
RECs need to be particularly attentive to these risks and
how to manage them. A first step is for researchers to
reflect on stigma and to identify their own prejudices
that might affect their research. Second, researchers
should be proactive in identifying potential risks and
strategies to mitigate them. In doing so, they should
think through each stage of the research—from the re-
search questions, to recruitment methods, study visits,
research procedures, and dissemination of results. Third,
risks at all of these stages should be considered at the
planning stage. For example, the dissemination plan
should be made before the research starts, not once data
is already in – even if adjustments have to be made
along the way. Fourth, researchers should be aware that
there may be additional or greater risks to stigmatized
groups and so a more exhaustive analysis may be valu-
able (for example, risks of being seen visiting the clinic,
risks of research procedures exacerbating stigma, risks
to family members). Again, this does not mean that the
research should not take place, nor that excessive pro-
tections should be instituted against risks that, when
carefully assessed, turn out to be highly speculative.
Fifth, engagement with affected individuals and commu-
nities is vital for the identification and mitigation of risk.
The extensive literature on community engagement and
good community participatory practice is a valuable re-
source for researchers working with stigmatized groups.
This analysis identified several outstanding challenges for
the ethical conduct of research with stigmatized groups or
on stigmatized conditions. Among these challenges are: (1)
whether and when it might be acceptable to develop inter-
ventions to reduce unhealthy behaviors by de-normalizing
them, at the risk of stigmatizing individuals who engage in
those behaviors; (2) how, if at all, researchers should access
the most severely stigmatized populations, when the stigma
is a significant barrier to recruitment and the risks posed by
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research that might inadvertently signal the status of partic-
ipants can be very high; and (3) best practices for minimiz-
ing risks to third parties, especially when dealing with
populations at high risk for secondary stigma. Solutions to
these outstanding ethical challenges are likely to be devel-
oped on a case-by-case basis so that they can be responsive
to context-specific factors. Nonetheless, as we hope we
have shown, even context-specific solutions can provide
generalizable lessons from which others in the stigma re-
search community can learn.
Abbreviations
FAS: fetal alcohol syndrome; FASD: fetal alcohol spectrum disorders;
MAO: monoamine oxidase; PrEP: pre-exposure prophylaxis; REC: research
ethics committee
Acknowledgements
The publication of this paper was supported by the Fogarty International
Center of the National Institutes of Health. We thank Nalini Anand, Ron
Bayer, the guest editors of this collection, and reviewers for the journal for
their helpful input, and Gretchen Birbeck and Deepa Rao for case studies.
Funding
The authors were individually supported by the institutions at which they
are employed. None of these bodies played a role in the conception or
writing of the paper.
Availability of data and materials
Not applicable.
Disclaimer
The ideas and opinions expressed are the authors’ own. They do not
represent any official position or policy of the National Institutes of Health,
Public Health Service, or Department of Health and Human Services.
Authors’ contributions
The authors jointly conceived the manuscript. MC, AM, and QAK contributed
case studies. JM drafted the manuscript. All authors revised the manuscript
for content and read and approved the final version of the manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Clinical Center Department of Bioethics, National Institutes of Health, 10/
1C118, 10 Center Drive, Bethesda, MD 20892, USA. 2Fogarty International
Center, National Institutes of Health, 31 Center Dr, Bethesda, MD 20892, USA.
3Department of Psychiatry and Mental Health, University of Cape Town,
J-Block, Groote Schuur Hospital, Observatory, Cape Town, South Africa.
4CONICET, Programa de Bioética, FLACSO Argentina, Tucumán 1966,
C1050AAN Caba, Argentina. 5Centre for the AIDS Program of Research in
South Africa, Doris Duke Medical Research Institute, Nelson R Mandela
School of Medicine, University of KwaZulu-Natal, Congella 4013, South Africa.
Received: 30 October 2018 Accepted: 1 April 2019
References
1. Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol. 2001;27:363–
85.
2. Achkar JM, Macklin R. Ethical considerations about reporting research results
with potential for further stigmatization of undocumented immigrants. Clin
Infect Dis. 2009;48:1250–3.
3. Tekola F, Bull S, Farsides B, Newport MJ, Adeyemo A, Rotimi CN, et al.
Impact of social stigma on the process of obtaining informed consent for
genetic research on podoconiosis: a qualitative study. BMC Med Ethics.
2009;10:13.
4. Council for International Organizations of Medical Sciences (CIOMS), World
Health Organization. International ethical guidelines for health-related
research involving humans. 4th ed. Geneva: CIOMS; 2016. https://cioms.ch/
shop/. Accessed 15 Jan 2018.
5. Canadian Institutes of Health Research, Natural Sciences and Engineering
Research Council of Canada, and Social Sciences and Humanities Research
Council of Canada. Tri-council policy statement: ethical conduct for research
involving humans. Ottawa: Government of Canada; 2014. http://www.pre.
ethics.gc.ca/pdf/eng/tcps2-2014/TCPS_2_FINAL_Web.pdf. Accessed 15 Jan
2018.
6. Hurst SA. Vulnerability in research and health care; describing the elephant
in the room? Bioethics. 2008;22:191–202.
7. Council for International Organizations of Medical Sciences (CIOMS), World
Health Organization. International ethical guidelines for biomedical research
involving human subjects. 3rd ed. Geneva: CIOMS; 2002. https://cioms.ch/
shop/. Accessed 15 Jan 2018.
8. Goldberg RE, Short SE. What do we know about children living with HIV-
infected or AIDS-ill adults in sub-Saharan Africa? A systematic review of the
literature. AIDS Care. 2016;28:130–41.
9. United Nations Children’s Fund (UNICEF). For every child, end AIDS. Seventh
stocktaking report 2016. New York: UNICEF; 2016. http://data.unicef.org/wp-
content/uploads/2016/12/HIV-and-AIDS-2016-Seventh-Stocktaking-Report.
pdf. Accessed 15 Jan 2018.
10. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et
al. Effectiveness and safety of oral HIV preexposure prophylaxis for all
populations. AIDS. 2016;30:1973–83.
11. Hall K, Sambu W. Demography of South Africa’s children. In: Jamieson L,
Berry L, Lake L, editors. South African child gauge. Cape Town: Children’s
Institute, University of Cape Town; 2017. p. 2017.
12. McClellan JM, Lehner T, King MC. Gene discovery for complex traits: lessons
from Africa. Cell. 2017;171:261–4.
13. Campbell MM, Susser E, Mall S, Mqulwana SG, Mndini MM, Ntola OA, et al.
Using iterative learning to improve understanding during the informed
consent process in a south African psychiatric genomics study. PLoS One.
2017;12:1–11.
14. Williams JF, Smith VC. Committee on substance abuse. Fetal alcohol
spectrum disorders. Pediatrics. 2015;136:e1395–406.
15. Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national,
regional, and global prevalence of alcohol use during pregnancy and fetal
alcohol syndrome: a systematic review and meta-analysis. Lancet Glob
Health. 2017;5:e290–9.
16. Levine C, Faden R, Grady C, Hammerschmidt D, Eckenwiler L, Sugarman J.
The limitations of “vulnerability” as a protection for human research
participants. Am J Bioeth. 2004;4:44–9.
17. Luna F. Elucidating the concept of vulnerability: layers not labels. IJFAB.
2009;2:121–39.
18. Crenshaw K. Demarginalizing the intersection of race and sex: a black
feminist critique of antidiscrimination doctrine, feminist theory and
antiracist politics. U Chi Legal F. 1989;1:139–67.
19. Luna F. Identifying and evaluating layers of vulnerability – a way forward.
Dev World Bioeth. 2018;00:1–10. https://doi.org/10.1111/dewb.12206.
20. DuBois JM, Beskow L, Campbell J, Dugosh K, Festinger D, Hartz S, et al.
Restoring balance: a consensus statement on the protection of vulnerable
research participants. Am J Public Health. 2012;102:2220–5.
21. Mann J, Tarantola D. Responding to HIV/AIDS: a historical perspective.
Health Hum Rights. 1998;2:5–8.
22. Bell E, Andrew G, Di Pietro N, Chudley AE, Reynolds JN, Racine E. It’s a
shame! Stigma against fetal alcohol spectrum disorder: examining the
Millum et al. BMC Medicine           (2019) 17:84 Page 8 of 9
ethical implications for public health practices and policies. Public Health
Ethics. 2015;9:65–77.
23. Bell E, Zizzo N, Racine E. Caution! Warning labels about alcohol and
pregnancy: unintended consequences and questionable effectiveness. Am J
Bioeth. 2015;15:18–20.
24. Eggertson L. Stigma a major barrier to treatment for pregnant women with
addictions. CMAJ. 2013;185:1562.
25. Wilkinson C, Room R. Warnings on alcohol containers and advertisements:
international experience and evidence on effects. Drug Alcohol Rev. 2009;
28:426–35.
26. Fong GT, Hammond D, Hitchman SC. The impact of pictures on the
effectiveness of tobacco warnings. Bull World Health Organ. 2009;87:640–3.
27. Hammond D, Fong GT, Zanna MP, Thrasher JF, Borland R. Tobacco
denormalization and industry beliefs among smokers from four countries.
Am J Prev Med. 2006;31:225–32.
28. Baha M, Le Faou AL. Smokers’ reasons for quitting in an anti-smoking social
context. Public Health. 2010;124:225–31.
29. Chambers SK, Dunn J, Occhipinti S, Hughes S, Baade P, Sinclair S, et al. A
systematic review of the impact of stigma and nihilism on lung cancer
outcomes. BMC Cancer. 2012;12:184.
30. Merriman T, Cameron V. Risk-taking: behind the warrior gene story. New
Zeal Med J. 2007;120:1250.
31. Gibbons A. Tracking the evolutionary history of a “warrior” gene. Science.
2004;304:818.
32. ‘Warrior gene’ blamed for Maori violence. Sydney Morning Herald; 2006.
https://www.smh.com.au/news/National/Warrior-gene-blamed-for-Maori-
violence/2006/08/08/1154802879716.html. Accessed 3 May 2018.
33. Reed E, Khoshnood K, Blankenship KM, Fisher CB. Confidentiality, privacy,
and respect: experiences of female sex workers participating in HIV research
in Andhra Pradesh, India. J Empir Res Hum Res Ethics. 2014;9:19–28.
34. Rothstein MA. Is deidentification sufficient to protect health privacy in
research? Am J Bioeth. 2010;10:3–11.
35. National Institutes of Health (NIH) Office of Extramural Research. Certificates
of confidentiality (CoC) – human subjects. Bethesda: NIH; 2017. https://
humansubjects.nih.gov/coc/index. Accessed 15 Jan 2018.
36. Sugarman J, Barnes M, Rose S, Dumchev K, Sarasvita R, Viet HT, et al.
Development and implementation of participant safety plans for international
research with stigmatised populations. Lancet HIV. 2018;5:e468–72.
37. Papas RK, Gakinya BN, Baliddawa JB, Martino S, Bryant KJ, Meslin EM, et al.
Ethical issues in a stage 1 cognitive-behavioral therapy feasibility study and
trial to reduce alcohol use among HIV-infected outpatients in western
Kenya. J Empir Hum Res Ethics. 2012;7:29–37.
38. Hausman D. Protecting groups from genetic research. Bioethics. 2008;22:
157–65.
39. Joint United Nations Programme on HIV/AIDS (UNAIDS). Policy brief: The
Greater Involvement of People Living with HIV (GIPA). Geneva: UNAIDS;
2007. http://data.unaids.org/pub/briefingnote/2007/jc1299_policy_brief_
gipa.pdf. Accessed 7 Mar 2019.
40. Tindana P, De Vries J, Campbell MM, Littler K, Seeley J, Marshall P, et al.
Community engagement strategies for genomic studies in Africa: a review
of the literature. BMC Med Ethics. 2015;16:24.
41. Campbell MM, Susser E, De Vries J, Baldinger A, Sibeko G, Mndini MM, et al.
Exploring researchers’ experiences of working with a researcher-driven,
population-specific community advisory board in a south African
schizophrenia genomics study. BMC Med Ethics. 2015;16:45.
42. Tindana PO, Singh JA, Tracy CS, Upshur RE, Daar AS, Singer PA, et al. Grand
challenges in global health: community engagement in research in
developing countries. PLoS Med. 2007;4:e273.
43. Kowal EE. Genetics and indigenous communities: ethical issues. 2nd ed.
International encyclopedia of the social and behavioral sciences. Elsevier
Science; 2015;9:962–968.
44. Rachlis B, Naanyu V, Wachira J, Genberg B, Koech B, Kamene R, et al.
Community perspectives of community health workers (CHWs) and their
roles in management for HIV, tuberculosis and hypertension in Western
Kenya. PLoS One. 2016;11:1–13.
Millum et al. BMC Medicine           (2019) 17:84 Page 9 of 9
